Oral doxifluridine plus levoleucovorin in elderly patients with advanced breast cancer

✍ Scribed by Emilio Bajetta; Laura Biganzoli; Carlo Carnaghi; Maria Di Bartolomeo; Ivo Spagnoli; Antonio Cassata; Emanuele Galante; Luigi Mariani; Corrado Gallo Stampino; Roberto Buzzoni

• Publisher: John Wiley and Sons
• Year: 1998
• Tongue: English
• Weight: 81 KB
• Volume: 83
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/(sici)1097-0142(19980915)83:6<1136::aid-cncr12>3.0.co;2-6

✦ Synopsis

BACKGROUND.

There currently is no agreement regarding the appropriate treatment of elderly patients with advanced breast carcinoma (ABC). Doxifluridine

(5-dFUR), a prodrug of 5-fluorouracil, has been found to be effective in this entity, but its use is limited by neurotoxicity and cardiotoxicity that are not observed when the oral formulation is used. The objective of this Phase II trial was to evaluate the effectiveness and tolerability of oral 5-dFUR, biomodulated with levoleucovorin (l-leucovorin), in elderly patients (age Ͼ 70 years) with ABC.